Compare BZFDW & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZFDW | IMNM |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | 611 | N/A |
| Industry | Movies/Entertainment | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.8B |
| IPO Year | 2021 | 2020 |
| Metric | BZFDW | IMNM |
|---|---|---|
| Price | $0.02 | $19.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $26.89 |
| AVG Volume (30 Days) | N/A | ★ 1.1M |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $5.15 |
| 52 Week High | N/A | $20.80 |
| Indicator | BZFDW | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 34.87 | 58.69 |
| Support Level | $0.02 | $18.87 |
| Resistance Level | $0.04 | $20.80 |
| Average True Range (ATR) | 0.00 | 1.22 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 1.14 | 70.80 |
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.